AMGNAmgen

Health care · Biotechnology · Nasdaq

Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) discovers, develops, manufactures and delivers innovative medicines to fight some of the world’s toughest diseases. 10-K, Item 1

Headquarters: Thousand Oaks, CA
CEO: Robert A. Bradway
Next results: around Feb 2, 2027

Compare with peers → Embed

RevenueFY2016–25 $36.8B+10.0% Highest in 10 years 10-K FY2025 · XBRL Net incomeFY2016–25 $7.7B+88.5% FY2024: $4.1B 10-K FY2025 · XBRL Free cash flowFY2016–25 $8.1B−22.1% FY2024: $10.4B 10-K FY2025 · XBRL Operating marginFY2016–25 24.7%+3.0 pts 42.6% in FY2016 10-K FY2025 · XBRL

What changed

10-K filed Feb 13, 2026 against Feb 14, 2025

Area	What changed	Source
Risk factors	17 new paragraphs, nothing like them in the previous 10-K	10-K Item 1A
Receivables growing faster than revenue	Receivables +41.1% vs revenue +10.0% (+31.2 pts)	10-K · XBRL
Accounting checks	10 other checks clear, 1 worth a look	10-K · XBRL
Insiders	No open-market buys in the last 90 days	Form 4
Filings	3 in the last 30 days	EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

What's new, in their words

10-K filed Feb 13, 2026

Paragraphs in Risk Factors that were not in the 10-K filed 2025-02-14. Quoted as filed.

OB3 includes significant provisions related to taxation, such as the permanent extension of certain expiring provisions of the 2017 Tax Act, and modifications to the international tax framework. This legislation has multiple effective dates, with certain provisions effective in 2026 and beyond. While we have incorporated the impact of…
10-K, Item 1A

All 17 new paragraphs →

Accounting checks

latest 10-K

10 of 11 clear 1 worth a look. Checks, not verdicts.

!
Receivables growing faster than revenueReceivables +41.1% vs revenue +10.0% (+31.2 pts)
✓
Cash from operations $10.0B vs net income $7.7B (FY ending 2025-12-31)
✓
Inventory -11.0% vs revenue +10.0% (-21.0 pts)
✓
Same auditor in both 10-Ks: Ernst & Young LLP
✓
No statement of substantial doubt about going concern
✓
No 8-K item 4.02 in the last 2 years
✓
No NT 10-K or NT 10-Q in the last 2 years
✓
The same matters as last year: F-1; Sales deductions; F-2; Unrecognized tax benefits
✓
No sentence in the 10-K concludes that controls were not effective because of a material weakness
✓
No 8-K item 2.06 in the last 2 years
✓
No 8-K item 1.03 in the last 2 years

How each check works, with sources →

In the last 30 days

All filings →

Nov 4, 202610-Q Quarterly report (10-Q) period ended Sep 30, 2026
Nov 3, 20268-K Quarterly results 8-K item 2.02
Oct 27, 20268-K Director or officer change 8-K item 5.02

Get an email when this changes: new risk paragraphs, accounting items, insider purchases, a new 10-K or 10-Q. RSS feed

Work on AMGN in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/AMGN/export.csv") into a cell.